Download PDF
Semin Liver Dis 2017; 37(04): 296-304
DOI: 10.1055/s-0037-1608775
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance

Nicole E. Rich
1   Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas
,
Neehar D. Parikh
2   Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
,
Amit G. Singal
1   Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2017 (online)

    Permissions and Reprints

Abstract

Overdiagnosis, the detection of clinically insignificant disease that would not otherwise impact the patient's lifespan, is a phenomenon that has been described in several solid tumors, such as prostate, breast, thyroid, and lung cancers. Population-based efforts to reduce hepatocellular carcinoma (HCC) mortality in cirrhosis patients by screening and early detection may result in the overdiagnosis of HCC. One of the harms of overdiagnosis is subsequent overtreatment, which can result in increased costs, as well as physical side effects, psychological harms, and poorer quality of life. In this review, the authors explore the potential for overdiagnosis in HCC.

Keywords

overdiagnosis - overtreatment - harms - surveillance - screening - HCC
 

  • References

  • 1 Mittal S, El-Serag HB. Epidemiology of HCC: consider the population. 2013; 47: S2-S6
    PubMedGoogle Scholar
  • 2 Ryerson AB, Eheman CR, Altekruse SF. , et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 2016; 122 (09) 1312-1337
    CrossrefPubMedGoogle Scholar
  • 3 Heimbach J, Kulik LM, Finn R. , et al. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology 2017
    PubMedGoogle Scholar
  • 4 European Association for the Study of the Liver; European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
    CrossrefPubMedGoogle Scholar
  • 5 Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ 2015; 350: g7773
    CrossrefPubMedGoogle Scholar
  • 6 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130 (07) 417-422
    PubMedGoogle Scholar
  • 7 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11 (04) e1001624
    CrossrefPubMedGoogle Scholar
  • 8 Costentin C, Layese R, Boursier V. , et al. Compliance to hepatocellular carcinoma screening guidelines in patients with compensated viral cirrhosis increases the probability of curative treatment and survival taking into account lead-time bias (ANRS CO12 CirVir Cohort). Paper presented at the International Liver Cancer Association 10th Annual Conference; September 9–11; Vancouver, Canada
    PubMedGoogle Scholar
  • 9 Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 2007; 41 (08) 777-782
    CrossrefPubMedGoogle Scholar
  • 10 Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52 (01) 132-141
    CrossrefPubMedGoogle Scholar
  • 11 Singal AG, Yopp A, , S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012; 27 (07) 861-867
    CrossrefPubMedGoogle Scholar
  • 12 Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57 (11) 1592-1596
    CrossrefPubMedGoogle Scholar
  • 13 Buscarini L, Fornari F, Bolondi L. , et al. Ultrasound-guided fine-needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. A retrospective study on 2091 biopsies. J Hepatol 1990; 11 (03) 344-348
    CrossrefPubMedGoogle Scholar
  • 14 Atiq O, Tiro J, Yopp AC. , et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 2017; 65 (04) 1196-1205
    CrossrefPubMedGoogle Scholar
  • 15 Verma AKM, Zhao B, Lok AS, Parikh ND. Frequency and work-up of indeterminate nodules during surveillance of hepatocellular carcinoma in patients with cirrhosis. Paper presented at the the Liver Meeting; November 11, 2016; Boston, MA
    PubMedGoogle Scholar
  • 16 Taylor EJ, Jones RL, Guthrie JA, Rowe IA. Modelling the benefits and harms of surveillance for hepatocellular carcinoma: information to support informed choices. Hepatology 2017
    PubMedGoogle Scholar
  • 17 Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 2016; 375 (15) 1438-1447
    CrossrefPubMedGoogle Scholar
  • 18 Bleyer A, Baines C, Miller AB. Impact of screening mammography on breast cancer mortality. Int J Cancer 2016; 138 (08) 2003-2012
    CrossrefPubMedGoogle Scholar
  • 19 Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014; 348: g366
    CrossrefPubMedGoogle Scholar
  • 20 Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 2010; 105 (09) 2079-2084
    CrossrefPubMedGoogle Scholar
  • 21 Uehara H, Nakaizumi A, Ishikawa O. , et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 2008; 57 (11) 1561-1565
    CrossrefPubMedGoogle Scholar
  • 22 Trinchet JC, Chaffaut C, Bourcier V. , et al; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54 (06) 1987-1997
    CrossrefPubMedGoogle Scholar
  • 23 Wang JH, Chang KC, Kee KM. , et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol 2013; 108 (03) 416-424
    CrossrefPubMedGoogle Scholar
  • 24 Forner A, Vilana R, Ayuso C. , et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47 (01) 97-104
    CrossrefPubMedGoogle Scholar
  • 25 Baek CK, Choi JY, Kim KA. , et al. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol 2012; 67 (02) 148-156
    CrossrefPubMedGoogle Scholar
  • 26 Roberts LR, Sirlin CB, Zaiem F. , et al. Imaging for the Diagnosis of Hepatocellular Carcinoma: a Systematic Review and Meta-analysis. Hepatology 2017
    PubMedGoogle Scholar
  • 27 Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (liver imaging reporting and data system): summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology 2015; 61 (03) 1056-1065
    CrossrefPubMedGoogle Scholar
  • 28 Simmons O, Fetzer DT, Yokoo T. , et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017; 45 (01) 169-177
    CrossrefPubMedGoogle Scholar
  • 29 Andriole GL, Crawford ED, Grubb III RLI. , et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13) 1310-1319
    CrossrefPubMedGoogle Scholar
  • 30 Schröder FH, Hugosson J, Roobol MJ. , et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360 (13) 1320-1328
    CrossrefPubMedGoogle Scholar
  • 31 Schröder FH, Hugosson J, Roobol MJ. , et al; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366 (11) 981-990
    CrossrefPubMedGoogle Scholar
  • 32 Schröder FH, Hugosson J, Roobol MJ. , et al; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384 (9959): 2027-2035
    CrossrefPubMedGoogle Scholar
  • 33 Moyer VA. ; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157 (02) 120-134
    CrossrefPubMedGoogle Scholar
  • 34 U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149 (03) 185-191
    CrossrefPubMedGoogle Scholar
  • 35 Carter HB, Albertsen PC, Barry MJ. , et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013; 190 (02) 419-426
    CrossrefPubMedGoogle Scholar
  • 36 Wilt TJ, Jones KM, Barry MJ. , et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 2017; 377 (02) 132-142
    CrossrefPubMedGoogle Scholar
  • 37 El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365 (12) 1118-1127
    CrossrefPubMedGoogle Scholar
  • 38 Villa E, Critelli R, Lei B. , et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 2016; 65 (05) 861-869
    CrossrefPubMedGoogle Scholar
  • 39 Kubota K, Ina H, Okada Y, Irie T. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 2003; 48 (03) 581-586
    CrossrefPubMedGoogle Scholar
  • 40 Sheu JC, Sung JL, Chen DS. , et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89 (02) 259-266
    CrossrefPubMedGoogle Scholar
  • 41 Taouli B, Goh JS, Lu Y. , et al. Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr 2005; 29 (04) 425-429
    CrossrefPubMedGoogle Scholar
  • 42 Barbara L, Benzi G, Gaiani S. , et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16 (01) 132-137
    CrossrefPubMedGoogle Scholar
  • 43 Huz JI, Melis M, Sarpel U. Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB 2012; 14 (08) 500-505
    CrossrefPubMedGoogle Scholar
  • 44 An C, Choi YA, Choi D. , et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol 2015; 21 (03) 279-286
    CrossrefPubMedGoogle Scholar
  • 45 Ko CW, Sonnenberg A. Comparing risks and benefits of colorectal cancer screening in elderly patients. Gastroenterology 2005; 129 (04) 1163-1170
    CrossrefPubMedGoogle Scholar
  • 46 Rex DK, Johnson DA, Lieberman DA, Burt RW, Sonnenberg A. ; American College of Gastroenterology. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroenterol 2000; 95 (04) 868-877
    PubMedGoogle Scholar
  • 47 Klabunde CN, Zheng Y, Quinn VP. , et al; PROSPR consortium. Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. Am J Prev Med 2016; 51 (03) e67-e75
    CrossrefPubMedGoogle Scholar
  • 48 Schenck AP, Peacock SC, Klabunde CN, Lapin P, Coan JF, Brown ML. Trends in colorectal cancer test use in the medicare population, 1998-2005. Am J Prev Med 2009; 37 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 49 Deshpande AD, McQueen A, Coups EJ. Different effects of multiple health status indicators on breast and colorectal cancer screening in a nationally representative US sample. Cancer Epidemiol 2012; 36 (03) 270-275
    CrossrefPubMedGoogle Scholar
  • 50 Marcus PM, Bergstralh EJ, Fagerstrom RM. , et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000; 92 (16) 1308-1316
    CrossrefPubMedGoogle Scholar
  • 51 Eggener SE, Scardino PT, Walsh PC. , et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185 (03) 869-875
    CrossrefPubMedGoogle Scholar
  • 52 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (03) 329-338
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Trevisani F, De Notariis S, Rapaccini G. , et al; Italian Liver Cancer Group. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97 (03) 734-744
    CrossrefPubMedGoogle Scholar
  • 54 Singal AG, Li X, Tiro J. , et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015; 128 (01) 90.e1-90.e7
    CrossrefPubMedGoogle Scholar
  • 55 Singal AG, Tiro JA, Marrero JA. , et al. Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma. Gastroenterology 2017; 152 (03) 608-615.e4
    CrossrefPubMedGoogle Scholar
  • 56 Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012; 156 (12) 841-847 , W295
    CrossrefPubMedGoogle Scholar
  • 57 Brett J, Bankhead C, Henderson B, Watson E, Austoker J. The psychological impact of mammographic screening. A systematic review. Psychooncology 2005; 14 (11) 917-938
    CrossrefPubMedGoogle Scholar
  • 58 Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer 2005; 104 (03) 467-478
    CrossrefPubMedGoogle Scholar
  • 59 Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28 (07) 1117-1123
    CrossrefPubMedGoogle Scholar
  • 60 Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101 (19) 1325-1329
    CrossrefPubMedGoogle Scholar
  • 61 Mayo SC, Shore AD, Nathan H. , et al. Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB 2011; 13 (07) 473-482
    CrossrefPubMedGoogle Scholar
  • 62 Ahmed S, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg 2016; 2016: 6120143
    CrossrefPubMedGoogle Scholar
  • 63 Kokudo N, Hasegawa K, Akahane M. , et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015; 45 (02) . DOI: 10.1111/hepr.12464.
    CrossrefPubMedGoogle Scholar
  • 64 Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver 2015; 9 (03) 267-317
    PubMedGoogle Scholar
  • 65 Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?. Hepatology 2011; 54 (06) 1998-2004
    CrossrefPubMedGoogle Scholar